PROTON RADIATION THERAPY RESEARCH

质子放射治疗研究

• 批准号: 3092950
• 负责人: JAY Steven LOEFFLER
• 金额: $ 350.53万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-08-01 至 1995-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3092950
• 关键词: human therapy evaluation; neoplasm /cancer radiation therapy; particle accelerators; proton beam; radiation therapy dosage; ultrasonography

The superior dose distributions which can be achieved by proton beams will be evaluated for their efficacy in clinical radiation therapy. The basis for interest is that for some anatomic sites, the proton treatment volumes will be smaller and conform more closely to the target volumes than is possible with photon beams. As a consequence, the dose to the target can be increased and hence also the tumor control probability. Since there will be less non-target normal tissues being irradiated, we anticipate that the frequency and severity of normal tissue damage will be reduced. In project 1 we employ Phase III and Phase II trials to test these dose distributions against diseases at several sites. In project 2 we will use the patient database acquired in project 1 to analyze the dose response relationships for normal tissues and tumors. Project 3 makes the other two projects possible; new treatment planning, delivery, and quality control measures will be developed and implemented to allow more efficient and even more precise treatments to be delivered. Clinical Trials (project 1) Existing clinical trials of proton beams will be continued and new trials begun. Existing trials are for treatment of 1) chordomas and chondrosarcomas of the base of skull and cervical spine and 2) stage T3-T4 carcinoma of the prostate. Phase II and III trials will be undertaken for: 1) glioblastoma multiform (90 CGE; 1.8 CGE bid) 2) T3 glottis (80 CGE, 1.6 CGE bid), 3) sarcomas involving S1-S2 (about 75 CGE qd), 4) uveal melanoma (70 vs 50 CGE) 5) benign recurrent meningioma (59.4 CGE vs 50.4 Gy), and 6) early rectal cancer (66.6 CGE vs 59.4 Gy). Other sites are under consideration. Clinical Investigations (project 2) Evaluations and analyses will be performed on the patient data from project 1 yielding quantitative information on: the dose-response of fully or partially irradiated normal tissues; and the tumor control under conditions of non-uniform irradiation of the target volume. In addition, comparative treatment planning studies will be performed which will suggest techniques for, and the benefit from, proton beam therapy at several sites and provide comparisons of various technologies for improving dose distributions. Physics (project 3) This project has two goals: 1) to develop techniques for better proton beam treatments through improvements in beam quality, treatment planning, treatment techniques and 2) to increase the speed and efficiency of proton beam therapy. When these goals are realized, tumor/sites will have been identified for which improved proton therapy leads to higher frequencies of tumor control and/or reduced morbidity.

可以通过质子束实现的上剂量分布将 评估其在临床放射疗法中的功效。 基础 引起关注的是，对于某些解剖部位，质子处理量 将更小，并且比IS更接近目标量 使用光子梁。 结果，对目标的剂量可以 增加肿瘤控制概率，从而增加。 从那以后 辐射的非目标正常组织将不太靶向，我们预计 正常组织损伤的频率和严重程度将降低。 在 项目1我们采用III期和II期试验来测试这些剂量 针对多个地点疾病的分布。 在项目2中，我们将使用 在项目1中获得的患者数据库以分析剂量反应 正常组织和肿瘤的关系。 项目3使其他两个 可能的项目；新的治疗计划，交付和质量控制 将制定和实施措施，以允许更有效，甚至 要提供的更精确的治疗方法。 临床试验（项目1）质子束的现有临床试验将 继续，新的试验开始。 现有的试验是1） 头骨和颈椎底部的丘多马斯和软骨肉瘤， 2）前列腺的T3-T4癌。 第二阶段和第三阶段的试验将是 进行：1）胶质母细胞瘤多形（90 cge; 1.8 CGE BID）2）T3 Glottis（80 CGE，1.6 CGE BID），3）涉及S1-S2的肉瘤（约75 CGE QD），4）卵子黑色素瘤（70 vs 50 CGE）5）良性复发性脑膜瘤（59.4 CGE vs 50.4 Gy）和6）早期直肠癌（66.6 CGE vs 59.4 Gy）。 其他 站点正在考虑。 临床研究（项目2）评估和分析将是 根据项目1的患者数据进行定量 信息：完全或部分辐照的正常的剂量反应 组织；以及在不均匀照射条件下的肿瘤控制 目标体积。 此外，比较治疗计划研究 将执行，这将为您提供的技术和受益 在多个地点的质子束治疗，并提供各种比较 改善剂量分布的技术。 物理（项目3）该项目有两个目标：1）开发技术 通过改进光束质量，可以更好地处理质子束处理 治疗计划，治疗技术和2）提高速度和 质子束治疗的效率。 当实现这些目标时，将确定肿瘤/部位 改善质子疗法会导致肿瘤控制的频率较高 和/或发病率降低。